AssetMark Inc’s Amneal Pharmaceuticals AMRX Stock Holding History

AssetMark Inc’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$443	Hold	22	–	–	﹤0.01%	3438
2026 Q2	$381	Hold	22	–	–	﹤0.01%	3336
2026 Q1	$273	Buy	+22	New	+$295	﹤0.01%	3284
2019 Q2	–	Sell	-1,495	Closed	-$21K	–	1332
2019 Q1	$21K	Sell	1,495 -37	-2%	-$489	﹤0.01%	872
2018 Q4	$21K	Sell	1,532 -312	-17%	-$5.62K	﹤0.01%	877
2018 Q3	$41K	Sell	1,844 -9	-0.5%	-$189	﹤0.01%	783
2018 Q2	$30K	Buy	+1,853	New	+$32.5K	﹤0.01%	828

Other funds holding AMRX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Tucker Asset Management Littleton, Colorado $406M AUM 20.49% 1-Year Est. Return

Quartz Partners Saratoga Springs, New York $330M AUM 17.57% 1-Year Est. Return

Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return

Signature Wealth Management Partners Montvale, New Jersey $234M AUM 23.06% 1-Year Est. Return

AssetMark Inc's AMRX Position: Q3 2026 in Review

AssetMark Inc held its Amneal Pharmaceuticals (AMRX) position steady in Q3 2026 at 22 shares worth $443. The position accounts for ﹤0.01% of the portfolio, ranked #3438.

AssetMark Inc first reported a position in AMRX in Q2 2018 and has held it in 7 quarters since. The position peaked at $41K in Q3 2018. 115 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

AssetMark Inc held 22 shares of Amneal Pharmaceuticals worth $443 as of Q3 2026.
AssetMark Inc left its Amneal Pharmaceuticals share count unchanged in Q3 2026.
Amneal Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3438 holding.
AssetMark Inc first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 7 quarters since.
AssetMark Inc's Amneal Pharmaceuticals position peaked at $41K in Q3 2018.
115 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.